Dr. Domchek on Promising Biomarkers in Breast Cancer

Susan Domchek, MD
Published: Tuesday, Jan 09, 2018



Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.

Biomarkers such as BRCA1/2 are currently used to determine treatment for patients with breast cancer, explains Domcheck.

Domcheck adds that if a patient is microsatellite instability-high (MSI-H), then that patient can receive pembrolizumab (Keytruda) regardless of tumor site.


Susan Domchek, MD, director of the Basser Center for BRCA at Penn Medicine, discusses promising biomarkers in breast cancer.

Biomarkers such as BRCA1/2 are currently used to determine treatment for patients with breast cancer, explains Domcheck.

Domcheck adds that if a patient is microsatellite instability-high (MSI-H), then that patient can receive pembrolizumab (Keytruda) regardless of tumor site.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x